Rossmore Private Capital acquired a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 460 shares of the biopharmaceutical company’s stock, valued at approximately $225,000.

A number of other large investors also recently modified their holdings of the business. Parkside Financial Bank & Trust boosted its position in shares of Regeneron Pharmaceuticals by 44.2% during the first quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 19 shares in the last quarter. Icon Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.8% during the first quarter. Icon Wealth Partners LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 24 shares in the last quarter. Raymond James Trust N.A. boosted its position in shares of Regeneron Pharmaceuticals by 3.4% during the fourth quarter. Raymond James Trust N.A. now owns 798 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 26 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,149 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 29 shares in the last quarter. Finally, Investment House LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.5% during the first quarter. Investment House LLC now owns 1,210 shares of the biopharmaceutical company’s stock valued at $591,000 after purchasing an additional 30 shares in the last quarter. 67.14% of the stock is currently owned by hedge funds and other institutional investors.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 214 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $449.01, for a total value of $96,088.14. Following the sale, the chief financial officer now owns 25,973 shares of the company’s stock, valued at $11,662,136.73. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Neil Stahl sold 10,349 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $452.26, for a total value of $4,680,438.74. Following the completion of the sale, the executive vice president now directly owns 36,380 shares in the company, valued at approximately $16,453,218.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 196,397 shares of company stock worth $109,206,506. Corporate insiders own 11.84% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock traded up $5.86 on Friday, hitting $576.72. 865,725 shares of the company were exchanged, compared to its average volume of 1,213,169. The stock has a market capitalization of $61.34 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 1.24 and a beta of 0.53. The company has a 50-day moving average price of $525.83 and a 200 day moving average price of $418.44. Regeneron Pharmaceuticals Inc has a 1-year low of $271.37 and a 1-year high of $581.78. The company has a quick ratio of 3.49, a current ratio of 4.21 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $6.13 by $0.47. The business had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.81 billion. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.45 EPS. Research analysts forecast that Regeneron Pharmaceuticals Inc will post 23.84 EPS for the current year.

REGN has been the subject of a number of recent research reports. Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $487.00 to $510.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Cfra lifted their price objective on Regeneron Pharmaceuticals from $460.00 to $487.00 and gave the company a “hold” rating in a research note on Wednesday, March 4th. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. SVB Leerink boosted their price target on Regeneron Pharmaceuticals from $604.00 to $622.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Finally, Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $540.00 to $575.00 in a research note on Tuesday, April 28th. Fourteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Buy” and a consensus target price of $515.26.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Compound Interest

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.